Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Journal Club
  • Published:

Finding the right treatment for neonatal abstinence syndrome: is this the right time?

Journal of Perinatology volume 38, pages 785–787 (2018)Cite this article

Subjects

Abstract

Neonatal abstinence syndrome (NAS) is a constellation of withdrawal symptoms in infants born to mothers with chronic opioid use during pregnancy. A proportion of infants will need pharmacotherapy in addition to non-pharmacological interventions. In this article, we reviewed a clinical trial comparing the use of sublingual buprenorphine to oral morphine (the most widely used pharmacotherapy for NAS) in term infants. The primary end point was the duration of treatment, and secondary end points were the length of hospital stay, the proportion of infants who needed supplemental phenobarbital, and safety.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Grossman MR, Berkwitt AK, Osborn RR, Xu Y, Esserman DA, Shapiro ED, Bizzaro MJ. An initiative to improve the quality of care of infants with neonatal abstinence syndrome. Pediatrics. 2017;139:e1–8.

    Article  Google Scholar 

  2. Hudak ML, Tan RC. Committee on Drugs, the Committee of Fetus and Newborn Neonatal drug withdrawal. Pediatrics. 2012;129:e540–60.

    Article  Google Scholar 

  3. Kraft WK, Gibson E, Dysart K, Damle VS, LaRusso JL, Greenspan JS, et al. Sublingual buprenorphine for treatment of the neonatal abstinence syndrome: a randomized trial. Pediatrics. 2008;122:e601–7.

    Article  Google Scholar 

  4. Kraft WK, Dysart K, Greenspan JS, Gibson E, Kaltenbach K, Ehrlich ME. Revised dose schema of sublingual buprenorphine in the treatment of the neonatal abstinence syndrome. Addiction. 2011;106:574–80.

    Article  Google Scholar 

  5. Marek E, Kraft WK. Ethanol pharmacokinetics in neonates and infants. Curr Ther Res. 2014;76:90–7.

    Article  CAS  Google Scholar 

  6. Behnke M, Smith V. Committee on Substance Abuse, Committee on Fetus and Newborn. Prenatal substance abuse: short- and long-term effects on the exposed fetus. Pediatrics. 2013;131:e1009–24.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics/Division of Newborn Medicine, Floating Hospital for Children at Tufts Medical Center, Boston, MA, 02111, USA

    Elizabeth Yen & Jonathan M. Davis

Authors
  1. Elizabeth Yen
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jonathan M. Davis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth Yen.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yen, E., Davis, J.M. Finding the right treatment for neonatal abstinence syndrome: is this the right time?. J Perinatol 38, 785–787 (2018). https://doi.org/10.1038/s41372-018-0090-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41372-018-0090-2

Search

Advanced search

Quick links